Advertisement

Topics

BLA Submitted to FDA for Biosimilar Candidate to Herceptin

08:05 EDT 1 Aug 2017 | PharmPro

Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to U.S. Food And Drug Administration. The biosimilar candidate to Herceptin (trastuzumab) was supported by Phase 3 data in patients with HER2-positive early breast cancer.
Contributed Author: 
Amgen

Original Article: BLA Submitted to FDA for Biosimilar Candidate to Herceptin

NEXT ARTICLE

More From BioPortfolio on "BLA Submitted to FDA for Biosimilar Candidate to Herceptin"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...